The impact of systemic therapy following ductal carcinoma in situ.
Following local therapy for ductal carcinoma in situ (DCIS), tamoxifen reduces the risk of ipsilateral and contralateral breast cancer by 30%-50%. Studies of tamoxifen in women with resected DCIS have not shown any effect on overall or cancer-specific survival. The adverse event profile of tamoxifen is well characterized, and individual risks and benefits should be assessed to guide decision making. We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies.
Department of Internal Medicine, Division of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
Jennifer
J
Eng-Wong
Joseph P
JP
Costantino
Sandra M
SM
Swain
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004967:Estrogens; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000517:prevention & control*; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011960:Receptors, Estrogen / Q000032:analysis; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen